[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling

In the completed phase I trial NCT01450384 combining the anti-folate pemetrexed and the multi-kinase inhibitor sorafenib it was observed that 20 of 33 patients had prolonged stable disease or tumor regression, with one complete response and multiple partial responses. The pre-clinical studies in thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, Laurence, Roberts, Jane L., Tavallai, Mehrad, Chuckalovcak, John, Stringer, Daniel K., Koromilas, Antonis E., Boone, David L., McGuire, William P., Poklepovic, Andrew, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029651/
https://www.ncbi.nlm.nih.gov/pubmed/27015562
http://dx.doi.org/10.18632/oncotarget.8281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029651/
https://www.ncbi.nlm.nih.gov/pubmed/27015562
http://dx.doi.org/10.18632/oncotarget.8281

Ejemplares similares